Evidence map›Paper›PMID 22267736›Full record

ArticleThe Journal of biological chemistry2012

Inhibin α-subunit N terminus interacts with activin type IB receptor to disrupt activin signaling.

Jie Zhu, S Jack Lin, Chao Zou, Yogeshwar Makanji, Theodore S Jardetzky, Teresa K Woodruff

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Evolving roles of activins and inhibins in ovarian cancer pathophysiology.American journal of physiology. Cell physiology · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Activins and Inhibins: Roles in Development, Physiology, and Disease.Cold Spring Harbor perspectives in biology · 2016
    Review
  9. Article
  10. Overcoming Insulin Insufficiency by Forced Follistatin Expression in β-cells of db/db Mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2015
    Article
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jie ZhuDepartment of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.
S Jack Lin
Chao Zou
Yogeshwar Makanji
Theodore S Jardetzky
Teresa K Woodruff
Northwestern University · USStanford University · US

Funding

TRANSCRIPTION FACTOR INTERACTIONS IN REPRODUCTIVE HORMONE GENE EXPRESSIONU54HD041857 · NICHD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WOODRUFF, TERESA K · 2003 to 2012
$12.2M
Inhibin Actions on Reproductive Target TissuesR01HD037096 · NICHD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WOODRUFF, TERESA K · 1999 to 2008
$2.3M
NICHD NIH HHS HD041857NICHD NIH HHS R01 HD037096NICHD NIH HHS R01 HD37096NICHD NIH HHS U54 HD041857
6 · The paper itself

Abstract

Inhibin is a heterodimeric peptide hormone produced in the ovary that antagonizes activin signaling and FSH synthesis in the pituitary. The inhibin β-subunit interacts with the activin type II receptor (ActRII) to functionally antagonize activin. The inhibin α-subunit mature domain (N terminus) arose relatively early during the evolution of the hormone, and inhibin function is decreased by an antibody directed against the α-subunit N-terminal extension region or by deletion of the N-terminal region. We hypothesized that the α-subunit N-terminal extension region interacts with the activin type I receptor (ALK4) to antagonize activin signaling in the pituitary. Human or chicken free α-subunit inhibited activin signaling in a pituitary gonadotrope-derived cell line (LβT2) in a dose-dependent manner, whereas an N-terminal extension deletion mutant did not. An α-subunit N-terminal peptide, but not a control peptide, was able to inhibit activin A signaling and decrease activin-stimulated FSH synthesis. Biotinylated inhibin A, but not activin A, bound ALK4. Soluble ALK4-ECD bioneutralized human free α-subunit in LβT2 cells, but did not affect activin A function. Competitive binding ELISAs with N-terminal mutants and an N-terminal region peptide confirmed that this region is critical for direct interaction of the α-subunit with ALK4. These data expand our understanding of how endocrine inhibin achieves potent antagonism of local, constitutive activin action in the pituitary, through a combined mechanism of competitive binding of both ActRII and ALK4 by each subunit of the inhibin heterodimer, in conjunction with the co-receptor betaglycan, to block activin receptor-ligand binding, complex assembly, and downstream signaling.

Indexed as

Activin Receptors, Type IActivin Receptors, Type IIAnimalsChickensCHO CellsCricetinaeCricetulusHumansInhibinsMaleMiceMutationPeptidesSignal TransductionActivin Receptors, Type IActivin Receptors, Type IIactivin receptor type II-AACVR1B protein, humanAcvr1b protein, mouseinhibin-alpha subunitInhibinsPeptides

Identifiers

PMID22267736
PMCPMC3318740
OpenAlexW1979085586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.